Search Results | Showing 21 - 30 of 120 results for "Biotech" |
| | | ... ASX-listed companies. The 35 stocks that make up the portfolio are from a variety of industries including commodities, mining, biotech, pharmaceuticals, tourism, finance and software. It includes Qantas Airways, Sonic Healthcare, Computershare and the ... |
| | | | Andrew and Nicola Forrest's Tattarang has backed new biotech venture capital group Tenmile to the tune of $250 million. The company will focus on supporting founders and companies building new, impactful health techbology and biotech solutions. Already ... |
| | | | Sydney-based Inventia Life Science has announced the super fund's direct investment as it develops, manufactures and distributes the RASTRUM 3D bioprinter. The bioprinter enables the scale-up production of 3D cell cultures for research and 3D cells ... |
| | | | UniSuper, the $106 billion industry fund, has made an investment with a venture capital fund manager. The fund has invested $75 million with early-stage commercialisation fund manager, Uniseed. The investment will feed into UniSuper's sustainable investment ... |
| | | | Chris Hall has taken on a new role with a biotechnology company after finishing up at Ellerston Capital last month. BiomeBank has announced the appointment of Chris Hall as the new chair for the clinical stage biotechnology company. He served as chief ... |
| | | | ... partnering with Chinese businesses include AstraZeneca, Pfizer and Novartis, while Chinese firms such as BeiGene and Legend Biotech have also found multinational partners. "Authorities have been pushing policies that encourage and incentivise domestic ... |
| | | | MSCI is launching a set of indices that target megatrends and innovation in the biotechnology and pharmaceutical industries. The partnership with Nasdaq-listed Royalty Pharma will measure the performance of companies focused on delivering new and innovative ... |
| | | | Four major superannuation funds are backing a biotech company that is developing a nasal spray that claims to prevent COVID-19 and the common cold. AustralianSuper, HESTA, Hostplus and Statewide Super have joined forces with CSL, a venture capital fund ... |
| | | | A biotech company backed by AustralianSuper, HESTA, Hostplus and Statewide Super has developed a new preventative treatment shown to reduce COVID-19 levels by up to 96%. The product, INNA-051, is being developed by Ena Respiratory, and works by stimulating ... |
| | | | ... outbreak of COVID-19. While around 20% is expected to benefit and thrive in the new world, including sectors like technology, biotech and any firm which is able to capture a "desire for change". "This is a shift from the 'two-speed economy' experienced ... |
|